Gyre TherapeuticsGYRE
13F holders, Q1 2024 (March 31)21holders
1famous investor
$17.47avg. 13F price*
At the end of Q1 2024, 21 institutions reported holding Gyre Therapeutics Inc. (GYRE) in their 13F filings. The largest holders were Vanguard Group Inc. ($3.4M), BlackRock Inc. ($3.0M) and Geode Capital Management, LLC ($2.8M). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Gyre Therapeutics Inc.
- CUSIP
- 403783103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $3.2M |
| Exits | 4 | $966K |
Ownership 21 holders
| Vanguard Group Inc. | 0.00% | Reduce -1.5% | 195,098 | $3.4M |
| BlackRock Inc. | 0.00% | Reduce -5.7% | 171,802 | $3.0M |
| Geode Capital Management, LLC | 0.00% | Add +19.5% | 160,589 | $2.8M |
| Millennium Management | 0.00% | New | 60,319 | $1.1M |
| Goldman Sachs Group Inc. | 0.00% | New | 46,093 | $806K |
| State Street Corp. | 0.00% | Add +182.7% | 40,538 | $709K |
| Jane Street Group, LLC | 0.00% | New | 30,555 | $534K |
| Marshall Wace, LLP | 0.00% | New | 25,544 | $447K |
| Northern Trust Corp. | 0.00% | Reduce -2.2% | 24,068 | $421K |
| JPMorgan Chase & Co. | 0.00% | Add +6758.9% | 20,028 | $350K |
| Balyasny Asset Management L.P. | 0.00% | New | 13,979 | $244K |
| Citigroup Inc. | 0.00% | Add +57.0% | 12,168 | $213K |
| Qube Research & Technologies Ltd | 0.00% | Reduce -7.6% | 6,235 | $109K |
| Morgan Stanley | 0.00% | New | 5,706 | $100K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +328.2% | 2,852 | $50K |
| BNP Paribas Financial Markets | 0.00% | New | 718 | $13K |
| Wells Fargo & Company | 0.00% | Add +2.1% | 96 | $2K |
| Towne Trust Company, N.A | 0.00% | New | 33 | $577 |
| Osaic Holdings, Inc. | 0.00% | No change | 14 | $245 |
| Macquarie Group Ltd. | 0.00% | New | 408 | $7 |
| Acadian Asset Management LLC | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is GYRE's weight in each manager's 13F, not the share of Gyre Therapeutics Inc. the manager owns.